Join to View Full Profile
1319 Punahou StPediatric Ambulatory UnitHonolulu, HI 96826
Phone+1 808-983-8551
Fax+1 808-983-8005
Dr. Wada is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Pediatric Hematology/Oncology, 1986 - 1989
Children's Hospital Los AngelesResidency, Pediatrics, 1985 - 1986- Childrens Hospital Los AngelesInternship, Transitional Year, 1983 - 1984
Emory University School of MedicineClass of 1983
Certifications & Licensure
HI State Medical License 1996 - 2026
CA State Medical License 1985 - 2020
American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma Start of enrollment: 2008 Jan 14
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Roles: Contact, Principal Investigator
- Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission Start of enrollment: 2012 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsMolecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.Giselle L Saulnier Sholler, Genevieve Bergendahl, Elizabeth C Lewis, Jacqueline Kraveka, William Ferguson
Genome Medicine. 2024-02-12 - 12 citationsEflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.Javier Oesterheld, William Ferguson, Jacqueline M Kraveka, Genevieve Bergendahl, Thomas Clinch
Journal of Clinical Oncology. 2024-01-01 - 1 citationsA phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma.Don Eslin, Peter E Zage, Genevieve Bergendahl, Elizabeth Lewis, William Roberts
International Journal of Cancer. 2023-09-01
Grant Support
- Regulation Of The N-MYC Oncogene In NeuroblastomaNational Institute Of Neurological Disorders And Stroke1996–2004
- Regulation Of The N MYC Oncogene In NeuroblastomaNational Institute Of Neurological Disorders And Stroke1997–1998
- Regulation Of The N-MYC Oncogene In NeuroblastomaNational Institute Of Neurological Disorders And Stroke1995–1996
- N-MYC Oncogene Regulation In Human NeuroblastomaNational Institute Of Neurological Disorders And Stroke1993–1995
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
